DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to tame aggressive lymphoma
Disease control Recruiting nowThis early-stage trial tests whether adding the targeted drug polatuzumab vedotin (with or without another drug, glofitamab) to standard chemotherapy is safe and tolerable for people with untreated, fast-growing B-cell lymphomas. About 56 participants will receive the combination…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New Three-Drug cocktail aims to tackle tough lymphoma
Disease control Recruiting nowThis early-phase trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) in about 30 adults with diffuse large B-cell lymphoma that has come back or not responded to prior therapy. The main goal is to find the safest dose and see if the com…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug cocktail shows promise for tough lymphoma
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy (EPOCH-R) is safe and effective for people with aggressive B-cell non-Hodgkin lymphoma. About 18 adults with untreated or minimally treated disease will receive the combination. The goal is to improve c…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
New CAR T-Cell therapy offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis trial tests a new treatment called WZTL-002 for people with large B-cell lymphoma that came back or didn't get better after standard chemo. It uses the patient's own immune cells, modified to fight cancer, and is given as a one-time infusion. About 60 adults aged 18 to 75 wi…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Malaghan Institute of Medical Research • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
Blood test may let some lymphoma patients stop chemo early
Knowledge-focused Recruiting nowThis study is for people newly diagnosed with a type of lymphoma called DLBCL. Researchers want to see if a blood test that tracks tumor DNA can help decide who can safely stop chemotherapy early. About 40 participants will get standard treatment, and those whose blood test shows…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: NA • Sponsor: Hua-Jay J Cherng, MD • Aim: Knowledge-focused
Last updated May 17, 2026 04:27 UTC